A keeper from the swamp: Justfactsmam Satur
Post# of 72446
(Total Views: 381)
Posted On: 04/23/2017 8:08:35 AM
Re: daydreaming2 #33202
A keeper from the swamp:
Justfactsmam Saturday, April 22, 2017 9:09:58 PM
Re: None Post #
179800
of 179838 Go
TAKE A TRIP DOWN MEMORY LANE...and witness REBIRTH OF SP WHEN THE SCIENCE WORKS: (Guess the Stock)
SIX MONTH TURNAROUND...then Going from $00.55 to $261.00... 46,000% increase
DESPAIR: (BAD NEWS at $2.44, SH burned) 12/21/07
Quote:
POST:
I- B- N
Friday, 12/21/07 07:40:36 PM
Re: None
Post # of 196
Ouch and it was going great !
Press Release Source: PharmaXXXXXXX, Inc.
PharmaXXXXXX Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Friday December 21, 6:59 pm ET
CRASH (ANNOUNCE REORGANIZATION...SP DROPS $2.44 to $0.55) 02/29/08
Quote:
surf1944
Friday, 02/29/08 12:54:08 PM
Re: None
Post # of 196
PharmaXXXXXXX Realigns to Focus on Advancing Expanded Pipeline of Promising Product Candidates (NOVEL IDEA...USE RESOURCES FOR TOP CANDIDATES)
Thursday February 28, 4:30 pm ET
SUNNYVALE, Calif., Feb. 28 /PRNewswire-FirstCall/ -- PharmaXXXXXXX, Inc. (Nasdaq: PCYC - News) today announced a corporate realignment to reduce expenses and focus its activities on advancing its expanded pipeline of promising new product candidates that address large market opportunities in cancer and immune-mediated diseases.
Ongoing mid-stage clinical trials of motexafin gadolinium (Xcytrin) are substantially complete and the company intends to partner or out-license the drug for further development. PharmaXXXXXXX will also reduce its workforce by approximately 40%.
Associated with this realignment,........s expects to make severance payments of approximately $0.4 million in the third quarter of fiscal 2008.
"We have sufficient cash to further enhance the value of our most promising product candidates, including our HDAC inhibitor in Phase 1 clinical trials and our Btk and Factor VIIa inhibitor compounds expected to enter the clinic in the third quarter of this year," said Richard A. Miller, M.D., president and chief executive officer of PharmaXXXXXXX. "We own the worldwide rights to these product candidates, which have unique features and are designed to inhibit validated targets important in cancer and immune mediated diseases."
TURN AROUND - GOOD TRIAL RESULTS...(phoenix from the ashes - SP DOUBLES TO $1.05 ) 06/05/08
Quote:
analogdog
Thursday, 06/05/08 10:59:24 PM
Re: None
Post # of 196
7:32AM PharmaXXXXXXX says Phase 1/2 trial of motexafin gadolinium plus antibody targeted radiation therapy demonstrates high complete response rate in patients with non-Hodgkin's lymphoma (PCYC) 1.05 : Co announces final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma who were treated with motexafin gadolinium in combination with Yttrium-90 Ibritumomab Tiuxetan, an approved antibody-targeted radiation therapy. The data were presented during the 10th International Conference on Malignant Lymphoma. Patients were treated with a standard dose of Zevalin administered with 2.5 to 5.0 mg/kg of MGd given for six days. Of 28 evaluable patients, 46 percent showed a complete response and 11 percent showed a partial response for an overall response rate of 57 percent. Rituximab refractory patients showed an overall response rate of 86 percent, with a 64 percent complete response rate and a median time to progression of 14 months. Adverse events seen were related to bone marrow suppression, an expected side effect of treatment with Zevalin.
BOOM! ( SP TRIPLES Dec.2010 $3.45, Doubles Dec.2011 $6.95, Then over 10 times Dec.2012 $64.00, DOUBLES AGAIN Dec 2013 to $135.00, Then $171 Jan.2015 ... then BOOM! BP...can't wait any longer... BUYOUT AT $261.68 )
Quote:
KingDMC Thursday, 03/05/15 07:05:28 AM
Re: noretreat post# 188
Post #
189
of 196 Go
AbbVie to Buy PharmaXXXXXXX in $21 Billion Deal -- 2nd Update
Source: Dow Jones News
By Jonathan D. Rockoff and Peter Loftus
AbbVie Inc. said late Wednesday it will buy cancer biotech PharmaXXXXXXX Inc. in a $21 billion deal that returns the North Chicago, Ill., drug company to deal-making after backing away from a big tax-lowering takeover last year.
The deal, a mix of cash and stock for $261.25 a share, would give AbbVie a presence in the multibillion-dollar blood-cancer market, and lessen its reliance on an aging rheumatoid-arthritis drug that accounts for most of its sales.
Justfactsmam Saturday, April 22, 2017 9:09:58 PM
Re: None Post #
179800
of 179838 Go
TAKE A TRIP DOWN MEMORY LANE...and witness REBIRTH OF SP WHEN THE SCIENCE WORKS: (Guess the Stock)
SIX MONTH TURNAROUND...then Going from $00.55 to $261.00... 46,000% increase
DESPAIR: (BAD NEWS at $2.44, SH burned) 12/21/07
Quote:
POST:
I- B- N
Friday, 12/21/07 07:40:36 PM
Re: None
Post # of 196
Ouch and it was going great !
Press Release Source: PharmaXXXXXXX, Inc.
PharmaXXXXXX Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Friday December 21, 6:59 pm ET
CRASH (ANNOUNCE REORGANIZATION...SP DROPS $2.44 to $0.55) 02/29/08
Quote:
surf1944
Friday, 02/29/08 12:54:08 PM
Re: None
Post # of 196
PharmaXXXXXXX Realigns to Focus on Advancing Expanded Pipeline of Promising Product Candidates (NOVEL IDEA...USE RESOURCES FOR TOP CANDIDATES)
Thursday February 28, 4:30 pm ET
SUNNYVALE, Calif., Feb. 28 /PRNewswire-FirstCall/ -- PharmaXXXXXXX, Inc. (Nasdaq: PCYC - News) today announced a corporate realignment to reduce expenses and focus its activities on advancing its expanded pipeline of promising new product candidates that address large market opportunities in cancer and immune-mediated diseases.
Ongoing mid-stage clinical trials of motexafin gadolinium (Xcytrin) are substantially complete and the company intends to partner or out-license the drug for further development. PharmaXXXXXXX will also reduce its workforce by approximately 40%.
Associated with this realignment,........s expects to make severance payments of approximately $0.4 million in the third quarter of fiscal 2008.
"We have sufficient cash to further enhance the value of our most promising product candidates, including our HDAC inhibitor in Phase 1 clinical trials and our Btk and Factor VIIa inhibitor compounds expected to enter the clinic in the third quarter of this year," said Richard A. Miller, M.D., president and chief executive officer of PharmaXXXXXXX. "We own the worldwide rights to these product candidates, which have unique features and are designed to inhibit validated targets important in cancer and immune mediated diseases."
TURN AROUND - GOOD TRIAL RESULTS...(phoenix from the ashes - SP DOUBLES TO $1.05 ) 06/05/08
Quote:
analogdog
Thursday, 06/05/08 10:59:24 PM
Re: None
Post # of 196
7:32AM PharmaXXXXXXX says Phase 1/2 trial of motexafin gadolinium plus antibody targeted radiation therapy demonstrates high complete response rate in patients with non-Hodgkin's lymphoma (PCYC) 1.05 : Co announces final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma who were treated with motexafin gadolinium in combination with Yttrium-90 Ibritumomab Tiuxetan, an approved antibody-targeted radiation therapy. The data were presented during the 10th International Conference on Malignant Lymphoma. Patients were treated with a standard dose of Zevalin administered with 2.5 to 5.0 mg/kg of MGd given for six days. Of 28 evaluable patients, 46 percent showed a complete response and 11 percent showed a partial response for an overall response rate of 57 percent. Rituximab refractory patients showed an overall response rate of 86 percent, with a 64 percent complete response rate and a median time to progression of 14 months. Adverse events seen were related to bone marrow suppression, an expected side effect of treatment with Zevalin.
BOOM! ( SP TRIPLES Dec.2010 $3.45, Doubles Dec.2011 $6.95, Then over 10 times Dec.2012 $64.00, DOUBLES AGAIN Dec 2013 to $135.00, Then $171 Jan.2015 ... then BOOM! BP...can't wait any longer... BUYOUT AT $261.68 )
Quote:
KingDMC Thursday, 03/05/15 07:05:28 AM
Re: noretreat post# 188
Post #
189
of 196 Go
AbbVie to Buy PharmaXXXXXXX in $21 Billion Deal -- 2nd Update
Source: Dow Jones News
By Jonathan D. Rockoff and Peter Loftus
AbbVie Inc. said late Wednesday it will buy cancer biotech PharmaXXXXXXX Inc. in a $21 billion deal that returns the North Chicago, Ill., drug company to deal-making after backing away from a big tax-lowering takeover last year.
The deal, a mix of cash and stock for $261.25 a share, would give AbbVie a presence in the multibillion-dollar blood-cancer market, and lessen its reliance on an aging rheumatoid-arthritis drug that accounts for most of its sales.
(1)
(0)